Clinical trials: Psychosis; Acute
Schizophrenia
Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia
The purpose of this study is to determine whether a low dose and a high dose of the study drug SCA-136 are effective and safe in the treatment of schizophrenia requiring hospitalization.
- Trial name
- NCT00265551
- Testing
- SCA-136 (200 mg), SCA-136 (400 mg), olanzapine (15 mg)
- Where
- 35 sites in United States
- Volunteers
- 300 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Social Anxiety Disorder
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
This U.S. multicenter, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate the efficacy, safety, and tolerability of a repeat intranasal (i.n.) dose of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to…
- Trial name
- NCT06809179
- Testing
- Fasedienol Nasal Spray - Fasedienol Nasal Spray
- Where
- 9 sites in United States
- Volunteers
- 61 people
- Sponsor
- VistaGen Therapeutics, Inc.
Schizophrenia
Amisulpride in Schizophrenic Acute Phase Patients
To collect the safety and response of using Amisulpride in acute schizophrenic patients
- Trial name
- ASAP (NCT00436371)
- Testing
- Amisulpride
- Where
- Hong Kong
- Volunteers
- 50 people
- Sponsor
- Sanofi
Schizophrenia
SB-773812 Administered In Adults With Schizophrenia
This is a two part study designed to evaluate the safety and efficacy of SB-773812 in the treatment of acute schizophrenia. Subjects with acute schizophrenia will be randomized in an adaptive design study to receive placebo…
- Trial name
- NCT00259870
- Testing
- SB-773812, Olanzapine
- Where
- 45 sites in United States, Belgium and 5 more
- Volunteers
- 338 people
- Sponsor
- GlaxoSmithKline
Schizophrenia
A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia
The purpose of this study is to evaluate the effectiveness and safety of paliperidone palmitate in schizophrenic inpatients who have experienced recent exacerbation of acute schizophrenia (that is within past 4 weeks).
- Trial name
- PREVAIL (NCT01527305)
- Testing
- Paliperidone palmitate
- Where
- 21 sites in China, Malaysia and 2 more
- Volunteers
- 212 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
The study will determine the efficacy of ALKS 9072 (also known as aripiprazole lauroxil or ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation.
- Trial name
- NCT01469039
- Testing
- ALKS 9072
- Where
- 84 sites in United States, Bulgaria and 6 more
- Volunteers
- 623 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study)
To evaluate efficacy and tolerability of Ziprasidone IM and oral in agitated patients with acute exacerbation of schizophrenia
- Trial name
- NCT00136994
- Testing
- Ziprasidone
- Where
- 34 sites in Italy
- Volunteers
- 160 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo.
- Trial name
- NCT00549718
- Testing
- Lurasidone HCl
- Where
- 48 sites in United States, France and 5 more
- Volunteers
- 489 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Acute Episode
An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)
This will be a randomized, placebo-controlled, parallel-group, multi-site, double-blind trial of elpipodect compared with placebo, using Risperidone as an active control.
- Trial name
- NCT03055338
- Testing
- Elpipodect, Risperidone
- Where
- 28 sites in United States
- Volunteers
- 224 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia
The purpose of this study is to evaluate the efficacy of paliperidone extended-release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with…
- Trial name
- PANDORA (NCT00761189)
- Testing
- Paliperidone
- Where
- 20 sites in South Korea
- Volunteers
- 491 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia
Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients
The primary objective of this study is to evaluate the efficacy of quetiapine fumarate extended-release (XR) used as mono-therapy, administered once daily, in the treatment of schizophrenic patient with acute episode.
- Trial name
- ESPRIT (NCT00882518)
- Testing
- Quetiapine Fumarate (SEROQUEL) Extended-Release (XR), Chlorpromazine
- Where
- 11 sites in China
- Volunteers
- 388 people
- Sponsor
- AstraZeneca
Schizophrenia
Long-term Study of Cariprazine in Patients With Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.
- Trial name
- NCT01104792
- Testing
- Cariprazine
- Where
- 86 sites in United States, Colombia and 4 more
- Volunteers
- 752 people
- Sponsor
- Forest Laboratories
Schizophrenia
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (15 mg QD and 30 mg QD) in…
- Trial name
- NCT05227703
- Testing
- Emraclidine 15 mg, Emraclidine 30 mg
- Where
- 26 sites in United States, Bulgaria and 1 more
- Volunteers
- 391 people
- Sponsor
- AbbVie
Schizophrenia, Schizoaffective Disorders
Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder
The purpose of this study is to determine whether increasing the amount (dose) of quetiapine IR (immediate release formulation) more rapidly than conventional dose increases, improves the control of symptoms as measured by the…
- Conditions
- Schizophrenia, Schizoaffective Disorders, Psychotic Disorders
- Trial name
- RAPID (NCT00457899)
- Testing
- Quetiapine IR (Immediate Release)
- Where
- 12 sites in United Kingdom
- Volunteers
- 234 people
- Sponsor
- AstraZeneca
Schizophrenia
Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia
This is a study to evaluate the safety, efficacy, and tolerability of cariprazine (RGH-188) relative to placebo in adult patients (18-60 years of age) with acute exacerbation of schizophrenia.
- Trial name
- NCT00694707
- Testing
- Cariprazine, Risperidone
- Where
- 65 sites in United States, India and 3 more
- Volunteers
- 732 people
- Sponsor
- Forest Laboratories
Psychotic Disorders
A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders
The primary purpose of the study is to compare therapy with antipsychotic medication (antipsychotic monotherapy or antipsychotic combination) versus no antipsychotic medication, and antipsychotic monotherapy versus antipsychotic…
- Trial name
- NCT05633108
- Testing
- No Intervention
- Where
- United Kingdom
- Volunteers
- 579,728 people
- Sponsor
- Eisai Co., Ltd.
Acute Schizophrenia
A Randomized, Active-controlled, Double-blind, Parallel-Goup Study of the Efficacy and Safety of Extended Release(ER) Paliperidone in the Treatment of Schizophrenia
This is a randomized (patients are assigned different treatments based on chance), double-blind (neither the patient nor the physician knows whether drug or placebo is being taken, or at what dosage), active-controlled…
- Trial name
- NCT00350467
- Testing
- ER OROS paliperidone and Olanzapine
- Where
- 7 sites in China
- Volunteers
- 288 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Schizophrenia
Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia
The purpose of this study is to compare the efficacy and tolerability of aripiprazole to olanzapine over 26 weeks for the treatment of schizophrenia
- Trial name
- NCT00712686
- Testing
- Aripiprazole, Olanzapine
- Volunteers
- 690 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo.
- Trial name
- NCT04072354
- Testing
- SEP-363856 50mg, SEP-363856 75mg
- Where
- 53 sites in United States, Bulgaria and 4 more
- Volunteers
- 463 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder, Mood Disorders
A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of 3 different doses of paliperidone extended release (ER) compared to placebo in patients diagnosed with Bipolar I Disorder who are experiencing an acute…
- Trial name
- NCT00299715
- Testing
- Paliperidone extended-release
- Volunteers
- 473 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.